SELEGILINE IN THE TREATMENT OF NARCOLEPSY

被引:67
作者
HUBLIN, C
PARTINEN, M
HEINONEN, EH
PUUKKA, P
SALMI, T
机构
[1] ORION CORP FARMOS, PHARMACEUT, SF-20101 TURKU, FINLAND
[2] ULLANLINNA SLEEP RES CTR, HELSINKI, FINLAND
关键词
D O I
10.1212/WNL.44.11.2095
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We treated 17 narcolepsy patients in a placebo-controlled, double-blind, crossover trial with 10-, 20-, 30-, and 40-mg daily doses of selegiline, a monoamine oxidase inhibitor widely used in Parkinson's disease. There was a dose-dependent as well as a statistically and clinically significant improvement in narcoleptic symptoms and polygraphic measures. At 40 mg, there was a 36% reduction in the number of daytime sleep episodes and a 34% reduction in their duration (compared with placebo, mean values). The number of excessive sleepiness episodes decreased by 43%, and the duration decreased by 47%. The number of cataplectic attacks was reduced by 89%. On the multiple sleep latency test, the REM sleep latency increased from 5.0 to 13.3 minutes, and the number of sleep-onset REM periods decreased from 3.1 to 0.6. Sleep (S1) latency was not changed. No intolerable adverse events occurred. The effective dose range was 20 to 40 mg, requiring a low-tyramine diet, which was easy to maintain. In conclusion, selegiline alleviates both main symptoms of narcolepsy-the abnormal sleep tendency and cataplexy. Thus, treatment with selegiline makes it possible to avoid polypharmacy and to use a potent stimulant without known addiction risk.
引用
收藏
页码:2095 / 2101
页数:7
相关论文
共 54 条
  • [1] DOPAMINE-RECEPTOR AUTORADIOGRAPHY OF HUMAN NARCOLEPTIC BRAIN
    ALDRICH, MS
    HOLLINGSWORTH, Z
    PENNEY, JB
    [J]. NEUROLOGY, 1992, 42 (02) : 410 - 415
  • [2] AUTOMOBILE ACCIDENTS IN PATIENTS WITH SLEEP DISORDERS
    ALDRICH, MS
    [J]. SLEEP, 1989, 12 (06) : 487 - 494
  • [3] ALDRICH MS, 1991, SLEEP RES A, V20, P280
  • [4] STATIC CHARGE SENSITIVE BED - NEW METHOD FOR RECORDING BODY MOVEMENTS DURING SLEEP
    ALIHANKA, J
    VAAHTORANTA, K
    [J]. ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY, 1979, 46 (06): : 731 - 734
  • [5] TURNOVER OF BRAIN MONOAMINE-OXIDASE MEASURED INVIVO BY POSITRON EMISSION TOMOGRAPHY USING L-[C-11]DEPRENYL
    ARNETT, CD
    FOWLER, JS
    MACGREGOR, RR
    SCHLYER, DJ
    WOLF, AP
    LANGSTROM, B
    HALLDIN, C
    [J]. JOURNAL OF NEUROCHEMISTRY, 1987, 49 (02) : 522 - 527
  • [6] EFFECTS OF BROMOCRIPTINE IN HUMAN NARCOLEPSY
    BOIVIN, DB
    MONTPLAISIR, J
    LAMBERT, C
    [J]. CLINICAL NEUROPHARMACOLOGY, 1993, 16 (02) : 120 - 126
  • [7] THE EFFECTS OF L-DOPA ON EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY
    BOIVIN, DB
    MONTPLAISIR, J
    [J]. NEUROLOGY, 1991, 41 (08) : 1267 - 1269
  • [8] COMPARISON OF THE PSYCHOSOCIAL EFFECTS OF EPILEPSY AND NARCOLEPSY CATAPLEXY - A CONTROLLED-STUDY
    BROUGHTON, RJ
    GUBERMAN, A
    ROBERTS, J
    [J]. EPILEPSIA, 1984, 25 (04) : 423 - 433
  • [9] GUIDELINES FOR THE MULTIPLE SLEEP LATENCY TEST (MSLT) - A STANDARD MEASURE OF SLEEPINESS
    CARSKADON, MA
    DEMENT, WC
    MITLER, MM
    ROTH, T
    WESTBROOK, PR
    KEENAN, S
    [J]. SLEEP, 1986, 9 (04) : 519 - 524
  • [10] GILLIN JC, 1976, NARCOLEPSY, P585